Product/Composition:- | Efavirenz + Emtricitabine + TDF |
---|---|
Strength:- | 600/200/300 mg |
Form:- | Tablet |
Reference Brands:- | Atripla(US/EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Atripla Tablets (Efavirenz 600 mg, Emtricitabine 200 mg, Tenofovir 300 mg) offer a once-daily, fixed-dose HIV treatment. Available via PharmaB2B platforms from WHO-GMP and USFDA-approved suppliers, Atripla is ideal for bulk procurement, tenders, and HIV programs. Ensure reliable supply from trusted global manufacturers.
Atripla Tablets combine Efavirenz (600 mg), Emtricitabine (200 mg), and Tenofovir Disoproxil Fumarate (300 mg) in a once-daily, fixed-dose antiretroviral therapy for HIV-1 infection. Widely recommended in global HIV treatment guidelines, Atripla simplifies adherence and improves patient outcomes. On PharmaB2B platforms, global pharmaceutical buyers, NGOs, and procurement agencies can source WHO-GMP and USFDA-approved Atripla formulations from trusted manufacturers. Ideal for tender supply, HIV programs, and institutional purchases, Atripla is available for bulk export at competitive prices. Partner with verified suppliers on PharmaB2B to ensure timely, compliant delivery of high-quality antiretrovirals essential for public health programs.